GlucoTrack, Inc.

NasdaqCM:GCTK Stock Report

Market Cap: US$2.0m

GlucoTrack Management

Management criteria checks 2/4

GlucoTrack's CEO is Paul Goode, appointed in Nov 2021, has a tenure of 4.67 years. total yearly compensation is $394.10K, comprised of 88.8% salary and 11.2% bonuses, including company stock and options. directly owns 0.005% of the company’s shares, worth $108.22. The average tenure of the management team and the board of directors is 3.8 years and 2.1 years respectively.

Key information

Paul Goode

Chief executive officer

US$394.1k

Total compensation

CEO salary percentage88.81%
CEO tenure4.7yrs
CEO ownership0.005%
Management average tenure3.8yrs
Board average tenure2.1yrs

Recent management updates

Recent updates

Seeking Alpha • Oct 10

GlucoTrack to start R&D program for glucose monitoring system

GlucoTrack (NASDAQ:GCTK) said it will begin a new R&D program for a long-term continuous glucose monitor to expand its product pipeline. Following a recent acquisition of certain related IP, GlucoTrack intends to develop a long-term implantable glucose management technology to address the Type 1 diabetes market, the company said in an Oct. 10 press release. GlucoTrack said it previously reported that it completed lab testing of its non-invasive GlucoTrack 2.0 clinical prototype system and saw better-than-expected accuracy and performance with the technology. The company is scheduled to begin its first-in-human trials later this quarter.

CEO Compensation Analysis

How has Paul Goode's remuneration changed compared to GlucoTrack's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2026n/an/a

-US$17m

Dec 31 2025US$394kUS$350k

-US$19m

Sep 30 2025n/an/a

-US$26m

Jun 30 2025n/an/a

-US$27m

Mar 31 2025n/an/a

-US$27m

Dec 31 2024US$350kUS$350k

-US$23m

Sep 30 2024n/an/a

-US$15m

Jun 30 2024n/an/a

-US$12m

Mar 31 2024n/an/a

-US$10m

Dec 31 2023US$483kUS$225k

-US$8m

Sep 30 2023n/an/a

-US$7m

Jun 30 2023n/an/a

-US$6m

Mar 31 2023n/an/a

-US$5m

Dec 31 2022US$540kUS$201k

-US$4m

Sep 30 2022n/an/a

-US$5m

Jun 30 2022n/an/a

-US$5m

Mar 31 2022n/an/a

-US$4m

Dec 31 2021US$29kn/a

-US$4m

Sep 30 2021n/an/a

-US$3m

Jun 30 2021n/an/a

-US$3m

Mar 31 2021n/an/a

-US$3m

Dec 31 2020US$1kn/a

-US$3m

Compensation vs Market: Paul's total compensation ($USD394.10K) is below average for companies of similar size in the US market ($USD649.34K).

Compensation vs Earnings: Paul's compensation has increased whilst the company is unprofitable.

CEO

Paul Goode (58 yo)

4.7yrs
Tenure
US$394,100
Compensation

Dr. Paul V. Goode, Ph.D. is Chief Technology Officer of EndoStim, Inc. Dr. Goode was Senior Vice President of Research and Development of EndoStim, Inc. Dr. Goode, serves as Chief Executive Officer at Gluc...

Leadership Team

NamePositionTenureCompensationOwnership
Paul Goode
CEO, President & Director4.7yrsUS$394.10k0.0054%
$ 108.2
Avner Gal
Co-Founder25.5yrsUS$187.39kno data
David Malka
Co-Founder25.5yrsUS$199.35kno data
Vincent Wong
Chief Operations Officer1.3yrsno data0.000020%
$ 0.4
Mark Tapsak
Chief Scientific Officer1.3yrsUS$176.21kno data
Drinda Benjamin
Vice President of Marketing3yrsno datano data
3.8yrs
Average Tenure
58yo
Average Age

Experienced Management: GCTK's management team is considered experienced (3.8 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Paul Goode
CEO, President & Director1.8yrsUS$394.10k0.0054%
$ 108.2
Avner Gal
Co-Founder9.3yrsUS$187.39kno data
Andrew Balo
Independent Director2.1yrsUS$114.00k0.075%
$ 1.5k
Luis Malave
Independent Chairman5.1yrsUS$134.00k0.065%
$ 1.3k
David Klonoff
Chair of Scientific Advisory Board5.3yrsno datano data
Erin Carter
Independent Director2.9yrsUS$114.00k0.034%
$ 685.3
Victoria Carr-Brendel
Independent Director1.2yrsUS$74.83k0.0069%
$ 138.4
Guillermo Umpierrez
Chair of Medical Advisory Board1.4yrsno datano data
Usman Latif
Member of Clinical Advisory Boardless than a yearno datano data
2.1yrs
Average Tenure
62.5yo
Average Age

Experienced Board: GCTK's board of directors are not considered experienced ( 2.1 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/01 17:33
End of Day Share Price 2026/06/30 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

GlucoTrack, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.